Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

269
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
269
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

659
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

929
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
929
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.2K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.2K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phototype-related Trichoscopic differences in lichen Planopilaris and frontal Fibrosing alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Prevalence of melasma, quality-of-life impact and social stigmatization.

Clinical and experimental dermatology·2026
Same author

Diagnosis and follow-up of the first case of Gaucher disease under enzyme replacement therapy in Senegal.

Ghana medical journal·2026
Same author

Trichoscopy of Cicatricial Alopecia in Fair and Dark Skin: A Multicenter International Study of the EADV Task Force on Hair Diseases and the IDS Task Force on Trichoscopy.

International journal of dermatology·2026
Same author

The need for African dermatology guidelines-Steps towards equitable care.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Investigation of an outbreak of acute algal-associated dermatoses among artisanal fishermen in Senegal: A one health approach.

PLOS global public health·2026

Related Experiment Video

Updated: May 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Antiphospholipid antibodies and systemic scleroderma.

Awa Oumar Touré1, Fatimata Ly2, Abibatou Sall1

  • 1laboratoire d'hématologie; Université Cheikh Anta Diop de Dakar (UCAD).

Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
|January 4, 2014
PubMed
Summary
This summary is machine-generated.

A high prevalence of antiphospholipid antibodies (APLs) was found in systemic scleroderma patients, suggesting a link between these conditions. Further monitoring for vascular complications in APL-positive scleroderma patients is recommended.

Keywords:
AntiphospholipidsSenegalSystemic sclerodermacomplication

More Related Videos

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

140.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

915

Related Experiment Videos

Last Updated: May 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

140.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

915

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Antiphospholipid antibodies (APLs) are implicated in vascular pathologies.
  • Systemic scleroderma is an autoimmune disease with potential vascular complications.

Purpose of the Study:

  • To investigate the prevalence of APLs in patients with systemic scleroderma.
  • To assess the association between APLs and clinical manifestations in systemic scleroderma.

Main Methods:

  • A cross-sectional descriptive study was conducted.
  • Blood samples from 40 systemic scleroderma patients were analyzed for APLs.
  • APLs assessed included IgG anti-β2 GPI, anticardiolipin, and lupus anticoagulants.

Main Results:

  • APLs were detected in 57.5% of the study population.
  • IgG anti-β2 GPI was the most frequent antibody (37.5%), followed by anticardiolipin (17.5%) and lupus anticoagulants (5%).
  • No statistically significant association was found between positive APL tests and specific scleroderma complications.

Conclusions:

  • A significant proportion of systemic scleroderma patients exhibit APLs, indicating a potential correlation.
  • Longitudinal studies are warranted to monitor vascular complications in systemic scleroderma patients with confirmed antiphospholipid syndrome.